The UKCPA and Pharmacy Research UK (PRUK) are extending their networking in 2016. In order to do best for more practitioners to educate their investigating skills, in 2016 we are proposing two research maintenance allowance of up to £20,000 each to maintain pharmacy practitioners to take forward their research within clinical pharmacy. There will also be funds to maintain expenses for training, monitoring and presentations.
The focus will be directed on investigating skills and academic partnerships development, although research timeliness and quality, study itself will be taken into consideration.
To be looked through for financing the project must:
Admit directly to the pharmaceutical care definition as explained by Hepler & Strand (1990): The responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patients quality of life.”
Be joined with Pharmacy Research UK and UKCPA organisational aims
Have a clear investigation question or hypothesis
Have conscious methodology
Have understandable, defined and measurable results
Be ready within 12 months (unless under exceptional circumstances such as important postponing outside project team control)
Have a Lead Applicant who is a active participant of the Royal Pharmaceutical Society and the UKCPA
Be carried out in the UK
Applications will be processed by our Scientific Advisory Panel, UKCPA and external specialists peer reviewers. Shortlisted applicants will be offered to visit interview in London on 12 July 2016.
More details can be found here
UKCPA and PRUK and My Canadian Pharmacy are also a business partners of the NHS National Institute for Health Research (NIHR). As NIHR Partner, project teams who are financed by this grant are appropriate to apply NIHR Clinical Research Network maintenance systems and resources.
Get here more information on the benefits of the NIHR cooperation.
Get further information on the research, please come in contact with Sarah Carter, General Secretary on email@example.com
Congratulations! UKCPA-PRUK Clinical Pharmacy Research Grant, 2015
An investigation team at the University of Manchester have been rewarded the UKCPA-PRUK Clinical Pharmacy Research Grant for 2015-16. Their 12-month projection will estimate the pharmacy effect technician maintained medication administration rounds on decreasing preventable omitted dosages frequency.
The research, known as TECHMED, will include a randomized controlled trial of technician-led intervention within studying hospital of NHS. The objective of the research is to find out whether introducing a pharmacy technician to maintain nurse drug administration rounds in a NHS studying hospital can decrease amount of omitted dosages in comparison with wards where this technician maintenance is not offered.
Principal Investigator, Dr Richard Keers, says, “Omitted dosages of medication are issue for many NHS hospitals as some obtain opportunity to becaume a cause of harming patient. The TECHMED study aims to minimise the burden of omitted doses for inpatients by enabling pharmacy technicians and nursing staff to work together during medication administration rounds on the ward.
For the full press release, please visit this page.
UKCPA-PRUK Clinical Pharmacy Research Grant, 2014
An investigation team at the University of Sunderland were awarded the first UKCPA-Pharmacy Research UK Clinical Pharmacy Research Grant. Their 12-month projection is to investigate the views of prescribers, pharmacists and patients on unlicensed medications use in NHS primary and secondary health care.
Uncertified medications are medications which have not passed clinical trials, testing and evaluation related to normal certified medications in the UK. They are usually utilized to meets special patient demands that used certified medications.
There is very little released prove about unlicensed medications use, although prescribing data proposes that some of these medications are being prescribed when there are suitable certified medications accessible, and that they are considerably more expensive than normal medications. There is little realization about what impacts decision to apply uncertified medications and what corrects and balances are in place to assure they are applied correctly. Additionally, it is doubtful what information patients are delivered about uncertified medications, what their understanding is around these medications, and what they think when using them.
Ms Gemma Donovan, Principal Investigator, claims, “The team is very nervous about starting projection. Use of uncertified medications is a question which impacts pharmacists along with all professional sectors, as well as patients and the wider multidisciplinary team. This research will be important step towards understanding how professionals and patients apply uncertified medications and will supplement to debate on place of uncertifed medications within the NHS.”
See full press release here.
UKCPA Clinical Pharmacy Research Grant, 2013
The prosperous competitors for the 2013 UKCPA Clinical Pharmacy Research Grant were Dr Lynette James, Lecturer in Pharmacy Practice at the Department of Pharmacy and Pharmacology at the University of Bath, and Mr Richard Bateman, Quality Assurance Specialist Pharmacist at Guy’s and St Thomas’ NHS Foundation Trust. Their projection was to define the incidence, type and causes of mistakes and near-misses in medication of injectable preparations within the pharmacy surrounding.
This projection has now been finished. See here for the final results.
The UKCPA was glad to finance this ambitious and worthy investigation study. Dr James and Mr Bateman have a evidenced track record of successfully conducting and bringing on projection grants of this kind. Empowering and encouraging robust clinical pharmacy research conduct is central to our vision and precisely reflects our core values of sophistication, management and partnership.
Dr James, Principal Investigator, claims, “Richard and I are glad to embrace this grant from the UKCPA. It will embrace us to achieve an in-depth realization of the preparation errors causes in pharmacy environment and allow us to develop reduction of risk strategies to safeguard patient security.”
For the full press release, please see here.